J Gastroenterol Hepatol:包囊性胰腺坏死经多孔道引流可改善预后

2013-11-30 MedSci MedSci原创

2013年11月刊发在J Gastroenterol Hepatol杂志上的一项回顾性研究结果显示,经内镜引流的包囊性胰腺坏死(WOPN),采用多孔道引流坏死组织可提高治疗的成功率,并且术后留置支架引流可降低胰液积液(PFC)复发。WOPN是一种包含胰腺和胰周坏死组织、具有界限分明炎性包膜结构的疾病,大多数WOPN为无菌性病变因此多采取保守治疗,无需介入治疗。介入治疗的适应症包括经抗生素治疗感染仍

2013年11月刊发在J Gastroenterol Hepatol杂志上的一项回顾性研究结果显示,经内镜引流的包囊性胰腺坏死(WOPN),采用多孔道引流坏死组织可提高治疗的成功率,并且术后留置支架引流可降低胰液积液(PFC)复发。

WOPN是一种包含胰腺和胰周坏死组织、具有界限分明炎性包膜结构的疾病,大多数WOPN为无菌性病变因此多采取保守治疗,无需介入治疗。介入治疗的适应症包括经抗生素治疗感染仍难以控制及保守治疗期间病情进一步加重。

临床上接受内镜治疗的WOPN患者的预后通常够理想。为了明确影响WOPN患者内镜治疗预后的因素,来自美国阿拉巴马大学的研究者对接受内镜治疗超过十年的WOPN患者进行了一项回顾性分析。

研究共纳入76名接受内镜治疗的患者,在传统引流组患者通过支架或鼻囊导管对坏死囊腔进行引流,多孔道引流技术(MTGT)组患者通过在胃或十二指肠上开孔进行多孔道引流。对于出现胰管离断综合征(DPDS)的患者,术后留置支架引流,以降低胰液积液(PFC)的复发。

结果显示,手术成功者有53例,MTGT组患者治疗的成功率显著高于传统引流组。经多重logistic回归分析显示,仅MTGT和减少内镜操作次数是手术成功与否的关键因素。支架留置组患者PFC的复发率显著低于无支架留置组的患者

研究者最后总结该研究带给临床以下启示:首先,对于坏死囊腔的冲洗引流,MTGT更占优势,因此治疗的短期预后较为理想;其次,尽管留置支架的拔除存在相关问题,但术后留置支架引流置可最大程度的降低PFC复发;最后,多学科密切合作可最大限度的改善患者预后。


原始出处:
Bang JY, Wilcox CM, Trevino J, Ramesh J, Peter S, Hasan M, Hawes RH, Varadarajulu S. Factors impacting treatment outcomes in the endoscopic management of walled-off pancreatic necrosis.J Gastroenterol Hepatol. 2013 Nov;28(11):1725-32.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1710685, encodeId=39241e1068535, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Nov 05 05:20:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063870, encodeId=b93420638e035, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Sep 14 09:20:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071514, encodeId=833220e151403, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 23 16:20:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675809, encodeId=df3116e5809a8, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Wed Oct 01 21:20:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362775, encodeId=07fd1362e75e5, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426569, encodeId=457b14265699b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1710685, encodeId=39241e1068535, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Nov 05 05:20:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063870, encodeId=b93420638e035, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Sep 14 09:20:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071514, encodeId=833220e151403, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 23 16:20:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675809, encodeId=df3116e5809a8, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Wed Oct 01 21:20:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362775, encodeId=07fd1362e75e5, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426569, encodeId=457b14265699b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1710685, encodeId=39241e1068535, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Nov 05 05:20:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063870, encodeId=b93420638e035, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Sep 14 09:20:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071514, encodeId=833220e151403, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 23 16:20:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675809, encodeId=df3116e5809a8, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Wed Oct 01 21:20:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362775, encodeId=07fd1362e75e5, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426569, encodeId=457b14265699b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=)]
    2014-09-23 许安
  4. [GetPortalCommentsPageByObjectIdResponse(id=1710685, encodeId=39241e1068535, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Nov 05 05:20:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063870, encodeId=b93420638e035, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Sep 14 09:20:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071514, encodeId=833220e151403, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 23 16:20:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675809, encodeId=df3116e5809a8, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Wed Oct 01 21:20:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362775, encodeId=07fd1362e75e5, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426569, encodeId=457b14265699b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=)]
    2014-10-01 wolongzxh
  5. [GetPortalCommentsPageByObjectIdResponse(id=1710685, encodeId=39241e1068535, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Nov 05 05:20:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063870, encodeId=b93420638e035, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Sep 14 09:20:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071514, encodeId=833220e151403, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 23 16:20:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675809, encodeId=df3116e5809a8, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Wed Oct 01 21:20:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362775, encodeId=07fd1362e75e5, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426569, encodeId=457b14265699b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=)]
    2013-12-02 millore
  6. [GetPortalCommentsPageByObjectIdResponse(id=1710685, encodeId=39241e1068535, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Nov 05 05:20:00 CST 2014, time=2014-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063870, encodeId=b93420638e035, content=<a href='/topic/show?id=94ffe853a7' target=_blank style='color:#2F92EE;'>#Gastroenterol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7853, encryptionId=94ffe853a7, topicName=Gastroenterol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Sep 14 09:20:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2071514, encodeId=833220e151403, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Sep 23 16:20:00 CST 2014, time=2014-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675809, encodeId=df3116e5809a8, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Wed Oct 01 21:20:00 CST 2014, time=2014-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362775, encodeId=07fd1362e75e5, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426569, encodeId=457b14265699b, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Mon Dec 02 04:20:00 CST 2013, time=2013-12-02, status=1, ipAttribution=)]
    2013-12-02 gwc384

相关资讯

JAMA Surgery:病灶大小或为无功能性胰腺神经内分泌瘤淋巴结累及的预测因子

研究要点: 放射学淋巴结状况及肿瘤分级是淋巴结转移的独立相关因素。在没有累积淋巴结情况的放射学影像证据时,NF-PanNET-G1患者的pN+风险非常低。术前肿瘤分级评估不达标时,病灶体积大小成为pN+的有力预测因子之一。 无功能性胰腺神经内分泌肿瘤(NF-PanNETs)诊断时往往表现为无淋巴结(LN)转移的无痛性肿块。因此对于低LN转移风险的患者人群,淋巴结切除术及手术范围应予限制并根据极

FDA批准酶替代药品Ultresa和Viokace

    2012年3月2日FDA批准了两种用于治疗胰腺功能缺陷的酶替代新药品。         两种新药品(Ultresa和Viokace)均属于胰酶脂肪酶类别,旨在帮助患者(导致胰功能不全的疾病)消化食物。         两种药品具体适应症有所不同。    

胰高血糖素样肽疗法升高胰腺炎风险

来源:医学论坛网   美国学者Michael Elashoff等,最近在《胃肠病学》(Gastroenterology)杂志上发表了一篇文章,显示使用基于胰高血糖素样肽-1(GLP-1 )的治疗会升高得胰腺炎的风险;应提高对于长期使用这些药物的潜在促胰腺癌发生的风险的警惕。   虽然人们担心使用基于胰高血糖素样肽-1疗法可能患胰腺炎、胰腺癌和甲状腺癌,但该类药物还是在2型糖尿病中得到

Lancet Oncology:儿童胰腺接受高剂量辐射或导致糖尿病风险增加

    欧洲的研究人员发现,儿童胰腺接受辐射可导致在几十年后发展为糖尿病的风险增加,特别是当暴露于高剂量辐射时。     根据法国古斯塔夫研究所 Florent de Vathaire博士和他的同事的研究,当胰腺的辐射剂量为1戈瑞时,估计以后发展为糖尿病的相对风险为1.61(95%可信区间1.21至2.68)。而根据研究人员报告在Lan

Diabetes :研究在骨髓中再造胰腺功能

一个意大利研究团队日前宣布,他们尝试在骨髓中部分再造胰腺功能获得成功,这将有助于糖尿病患者在胰腺切除手术后提高生活质量、降低并发症风险。最新出版的学术期刊《糖尿病》刊登了这一发现。 米兰圣拉斐尔医院的这个研究团队修改了针对1型糖尿病患者的胰岛移植程序。他们从捐赠者的胰腺中提取内分泌细胞,植入患者的盆骨骨髓中,“再造”部分胰腺功能。目前,研究团队已经在4位胰腺全部切除的糖尿病患者身上进行了临床试验

胰腺术后常见并发症防治专家共识解读

  前言   胰腺的解剖位置深,周围毗邻重要脏器及大血管,手术难度大,以往胰腺手术死亡率高达10%~20%。随着技术的进步,胰腺手术的安全性得到逐步提高,手术死亡率降至5%以下。胰十二指肠切除术等重大胰腺手术在各级医院得到逐步开展和推广,但其术后并发症发生率仍高达30%~50%。   为规范胰腺术后并发症的诊断及分级标准,指导临床实践,2010年中华医学会外科学分会胰腺外科学组牵头,组织国内各